U.S. Markets closed

Sinovac Biotech Ltd. (SVA)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
6.85-0.02 (-0.29%)
At close: 3:59PM EDT
People also watch
CAASCBAKCNTFJRJCACTS
  • but🌱the🌱key🌱to🌱failure🌱is🌱trying🌱to🌱please🌱everybody." http://dataunion.tistory.com/3353

    Sinovac Biotech Ltd. NASDAQ : SVA Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.7 In other words, the correlation coefficient of the other stock
    dataunion.tistory.com
  • Vaccine maker Protein Sciences is being acquired by Sanofi for around 20X's sales.
    SVA should be, at a minimum, $20 a share.
  • Nice to see a public statement by a major holder in favor of the competing $8 bid. Hope this spurs the Yin group to step up their bid substantially as a counter-offer.
    http://archive.fast-edgar.com//20170707/AEAZ922CI222W2ZB222M2WZZ4QF7Z2Y2ZL92/

  • "CAGED MONKEY Silent in Mourning the Recent Death of CAGED MONKEY's Family Members"... HOW? Gracias
  • Option traders pay a visit to CreditSpreads.io, absolutely free live list of mathematically profitable option credit spreads for the coming four weeks, sometimes including spreads for SVA! High-probability option credit spreads present an effective way to invest with determined risk and the maximum profit gained up front. CreditSpreads.io targets only the credit spreads which meet its rigid criteria for probability and profit, and ensures sustained profitability by telling you of any approaching events which might affect the trade. www.creditspreads.io

    CreditSpreads.io
    Sustainable, high probability, defined risk stock option trading opportunities.
    www.creditspreads.io
  • CDC Weekly --- CAGED MONKEY Come Out Mourning the Recent Death of CAGED MONKEY's Family Members
  • CDC Weekly --- CAGED MONKEY Silent in Mourning the Recent Death of CAGED MONKEY's Family Members
  • Shandong Sinobioway's consortium makes an offer to take Sinovac Biotech private at $8. Let the bidding war begin!
  • I didn't know Sinobioway had such close ties to SVA...

    "Another Chinese biologics drugmaker affiliated with Peking University, Sinobioway entered the bid soon after Yin made his offer. In fact, it was Sinobioway that raised the offer to $7 a share in its first offering. The relationship between the two companies goes way back to 1994 when Sinobioway salvaged a failing biologics company that later became the Sinovac we see today. Sinobioway Group's chairman Aihua Pan, who played a key role in Sinovac's revival, is also Sinovac Beijing's chairman. According to Sinovac’s 2015 annual report filed to the SEC, Sinobioway Biomedicine owns a 26.91% interest in Sinovac Beijing, the company’s principal operating subsidiary and where Yin presides as GM."

    http://www.fiercebiotech.com/biotech/sinovac-to-go-private-as-bribery-concerns-hint-investor-class-action-lawsuits

    Sinovac to go private as bribery concerns hint at investor class-action lawsuits | FierceBiotech
    A group of buyers is challenging a definitive privatization agreement Nasdaq-listed Chinese vaccine maker Sinovac reached with its chairman and CEO Weidong Yin, while the buyout is further complicated by a bribery case that Yin was involved in.
    www.fiercebiotech.com
  • Seems to me we just have to sit tight for a while. I can't see SVA putting the $7 offer to a vote when there is a counteroffer of $8. So Yin and his buddies at the very least will need to up their offer to $8, or maybe even a little better. On the plus side the movement of the stock to close to the $7 offer price means that all these buyers here are not looking for .10-.15 profits but expect to get at least 8. I personally would not sell at 7 and still think shareholders should be compensated at least 10 pershare. That said I might consider a yes vote close to 8+ since the company has done a bang up job of spreading fear and uncertainty to keep the price down for accumulation by their buddies. That game is over for the moment. I've owned this stock for a long time. I can remain patient for now.
  • ZM Daily --- CAGED MONKEY Silent in Mourning the Recent Death of CAGED MONKEY's Family Members
  • How about a conspiracy theory?: Gin up some bribery charges, fail to meet ER deadlines, don't release any info on HFMD sales, drive the stock lower, let your buddies pick up some cheap shares, offer a 30% premium to depressed stock prices so people feel happy, then make some real money after going private. Nah - that wouldn't happen.
  • PRWired --- CAGED MONKEY Silent in Mourning the Recent Death of CAGED MONKEY's Family Members
  • I'm sure everybody here has read this from last year..... I am curious if they will have anything to say.

    http://www.hengreninvestment.com/images/documents/Heng_Ren_Letter_to_Sinovac_SC_September_27-English.pdf

  • LOAD UP SOME OF IGXT AS WELL MAJOR BREAKOUT IMMINENT ...
    IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • $7 is better than 4.50 ??? It would of been nict to see the sales numbers. Not sure how to feel about this..LOL
  • NEWS ==> HR Upgrades PAY SCALE of CAGED MONKEY Board Posting To That of Public Toilet Cleaning ... NIC
  • Good To See Local Zoo CAGED MONKEY Put On Different Dress and Dance for Tourist ... L O L
  • HR Policy -- After 5:00 PM , Office Close ... No CAGED MONKEY To Put on Dresses and Dance -- NIC
  • I've been in SVA since 2009 and now getting solicitations to join the lawsuit. Does anyone have experience with this? Which firm is better than the other? ANY advise would be appreciated.